Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii-specific immunoglobulin G antibodies.

Meroni, V; Genco, F; Tinelli, C; Lanzarini, P; Bollani, L; Stronati, M; Petersen, E

Meroni, V; Genco, F; Tinelli, C; Lanzarini, P; Bollani, L; Stronati, M; Petersen, E.

Affiliation

Meroni V; Department of Infectious Diseases, University of Pavia, Pavia, Italy. v.meroni@smatteo.pv.it

Clin Vaccine Immunol ; 16(10): 1517-20, 2009 Oct.

Article in En | MEDLINE | ID: mdl-19692628

Subject(s)

Antibodies, Protozoan/biosynthesis; Coccidiostats/therapeutic use; Pregnancy Complications, Parasitic/immunology; Spiramycin/therapeutic use; Toxoplasma/immunology; Toxoplasmosis/complications; Toxoplasmosis/drug therapy; Adult; Antibody Affinity; Antibody Specificity; Case-Control Studies; Female; Humans; Immunoglobulin G/biosynthesis; Pregnancy; Time Factors; Toxoplasmosis/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Toxoplasma / Antibodies, Protozoan / Spiramycin / Toxoplasmosis / Pregnancy Complications, Parasitic / Coccidiostats Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Pregnancy Language: En Year: 2009 Type: Article

Fulltext

XML

PubMed Links

Search on Google